20 articles
Novel nanoparticle combines protein degrader with light therapy to reprogram cancer metabolism and eliminate breast tumors.
Leading cancer experts reveal breakthrough strategies combining radiation with immune treatments to boost cancer-fighting effectiveness.
A phase 3 trial finds scheduling immunochemotherapy before 3 PM nearly doubles progression-free and overall survival in NSCLC patients.
Scientists develop safer way to deliver immune-boosting genes directly to tumors, enhancing radiation therapy effectiveness.
A multinational study of 4,913 patients finds EBRT delivers survival outcomes comparable to surgery and ablation for early hepatocellular carcinoma.
Researchers developed a new radiotracer that targets cancer cells more effectively when combined with mTOR inhibition therapy.
Phase I trial shows NT-I7 safely increases lymphocyte counts and expands cancer-fighting T cells in high-grade glioma patients.
Inhibiting the mitophagy kinase PINK1 amplifies mitochondrial ROS, activating a BAX-caspase-GSDME cascade that destroys neuroblastoma cells via pyroptosis.
Quantum computing breakthrough accelerates development of photodynamic therapy drugs for cancer treatment in major healthcare competition.
New study reveals optimal timing strategy for combining radiation and immunotherapy treatments in advanced lung cancer patients.
Engineered green tea compound nanoparticles activate cellular powerhouses to suppress tumor growth and improve immune response against melanoma.
RO7300490, a FAP-targeted CD40 agonist, proved manageable in 80 advanced cancer patients but produced no objective tumor responses despite clear immune activation.
Phase 1 trial shows MP0317 activates anti-tumor immunity in solid tumors with a favorable safety profile, supporting combination therapy.
New review reveals how targeting mitochondria in cancer cells could overcome immunotherapy resistance and enhance anti-tumor responses.
Blocking CysLTR1 reprograms immunosuppressive neutrophils and reverses resistance to anti-PD1 checkpoint therapy in mice.
New approach targets specific cancer sites in advanced lung cancer patients, potentially improving outcomes.
New nanotechnology selectively destroys cancer cell mitochondria, making tumors more vulnerable to T cell attacks across multiple cancer types.
Researchers report on ezabenlimab treatment combined with chemotherapy and radiation for stage 3 anal cancer patients.
New research shows brief fasting periods can boost the effectiveness of cancer immunotherapy by reshaping tumor-fighting immune cells.
RSL3-induced ferroptosis degrades SHP2 via chaperone-mediated autophagy, amplifying IFN-ฮณ/STAT1 signaling and enhancing anti-PD-1 immunotherapy efficacy.
